47 related articles for article (PubMed ID: 25367763)
1. Differential impact of bortezomib on HL-60 and K562 cells.
Kliková K; Štefaniková A; Pilchová I; Hatok J; Chudý P; Chudej J; Dobrota D; Račay P
Gen Physiol Biophys; 2015 Jan; 34(1):33-42. PubMed ID: 25367763
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of HSP90β induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis.
Park S; Jeon JH; Park JA; Choi JK; Lee Y
Cell Stress Chaperones; 2021 Jan; 26(1):129-139. PubMed ID: 32869129
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents.
Altıntop MD; Cantürk Z; Özdemir A
ACS Omega; 2023 Nov; 8(45):42867-42877. PubMed ID: 38024728
[TBL] [Abstract][Full Text] [Related]
4. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.
Fall DJ; Stessman H; Patel SS; Sachs Z; Van Ness BG; Baughn LB; Linden MA
J Cancer; 2014; 5(9):720-7. PubMed ID: 25368671
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Sonneveld P; Asselbergs E; Zweegman S; van der Holt B; Kersten MJ; Vellenga E; van Marwijk-Kooy M; Broyl A; de Weerdt O; Lonergan S; Palumbo A; Lokhorst H
Blood; 2015 Jan; 125(3):449-56. PubMed ID: 25398935
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
8. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
[TBL] [Abstract][Full Text] [Related]
9. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Kaneko H; Yagi H; Shibayama H; Tanaka H; Kosugi S; Uoshima N; Kobayashi M; Adachi Y; Ohta K; Ishii K; Uchiyama H; Matsuda M; Nakatani E; Tsudo M; Shimazaki C; Takaori-Kondo A; Nomura S; Matsumura I; Taniwaki M; Kanakura Y;
Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos MA; Swern AS; Li JS; Hussein M; Weiss L; Nagarwala Y; Baz R
Blood Cancer J; 2014 Nov; 4(11):e257. PubMed ID: 25382609
[TBL] [Abstract][Full Text] [Related]
11. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Ludwig H; Rauch E; Kuehr T; Adam Z; Weißmann A; Kasparu H; Autzinger EM; Heintel D; Greil R; Poenisch W; Müldür E; Zojer N
Haematologica; 2015 Mar; 100(3):385-91. PubMed ID: 25398836
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
[No Abstract] [Full Text] [Related]
15. HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
Tao W; Chakraborty SN; Leng X; Ma H; Arlinghaus RB
Genes Cancer; 2015 Jan; 6(1-2):19-29. PubMed ID: 25821558
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
An G; Acharya C; Deng S; Yi S; Xu Y; Qin X; Sui W; Li Z; Shi L; Zang M; Feng X; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Tai YT; Qiu L
Exp Hematol; 2015 Mar; 43(3):168-176.e2. PubMed ID: 25462022
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
Ong SY; Ng HY; Surendran S; Linn YC; Chen Y; Goh YT; Diong C; Gopalakrishnan SK
Br J Haematol; 2015 Jun; 169(5):754-6. PubMed ID: 25413901
[No Abstract] [Full Text] [Related]
19. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
